Saturday, November 1409:00 – 09:3030 minOpen Pres.
Sun Pharma Canada Inc.
Sun Pharma Canada Inc.
3 sessions on Saturday, November 14Sun Pharma has been proudly operating in Canada since 2015 with our commercial headquarters located in Mississauga, Ontario. Our manufacturing facility located in Brampton, Ontario produces millions of doses each year for patients in Canada and global markets. Sun Pharma Canada Inc. has long-standing relationships with healthcare professionals, patient advocates, leading wholesalers, distributors, retail and specialty pharmacies, and payors, underscoring our strong presence and relationships across the country.
Combining our global presence with our local manufacturing and distribution enables us to deliver high-quality, affordable therapies that meet the highest regulatory standards.
To better address the unmet needs of patients, Sun Pharma Canada Inc. continues to invest strategically in its Innovative Medicines business. Our Innovative Medicines business features a portfolio of 6 brands across multiple therapeutic areas, including medical dermatology, biologics, oncology and ophthalmology.
Sessions at Dermatology Update — Fall 2026
3 sessions
Saturday, November 1409:35 – 10:0530 minOpen Pres.
Shedding Light on AK Management with PDT
Photodynamic therapy (PDT) remains an important treatment option for actinic keratosis (AK), offering a field-directed approach that can address both clinical and subclinical disease. In this expert panel discussion, leading Canadian dermatologists will review the evolving role and benefits of PDT in AK management. Attendees will gain an early look at key recommendations from the newly published Canadian PDT consensus paper developed by national experts to support best practices in clinical care and explore emerging evidence and unmet needs in post-PDT patient care.
Learning objectives
- Review the role of photodynamic therapy (PDT) and its benefits in the management of actinic keratosis (AK), highlighting patient selection considerations, and real-world practice experience
- Discuss key recommendations from the new Canadian PDT consensus paper, including best practices aimed at optimizing treatment outcomes and standardizing PDT use across clinical settings
- Explore emerging evidence and unmet needs in post-PDT patient care
Saturday, November 1414:20 – 14:5030 minOpen Pres.
High-Impact Psoriasis: From Clinical Evidence to Real-World Practice
Learning objectives
- Recognize the clinical impact and management considerations of psoriasis involving high-impact sites, including the scalp and nails.
- Apply evidence and practical clinical considerations to treatment decisions for patients with psoriasis involving high-impact sites
- Integrate clinical trial and real-world evidence into individualized treatment decisions to support effective long-term management of psoriasis.